At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients With Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
In Brief
A Phase 2 clinical trial evaluating Afatinib, Biopsy Procedure, and 5 other interventions for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 19 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial tests how well afatinib works in treating patients with cancer that has certain genetic changes. Afatinib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the EGFR gene. It works by blocking the action of mutated EGFR that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
Study Details
Timeline
Interventions
Given PO
Undergo biopsy
Undergo blood sample collection
Undergo CT scan
Undergo ECHO
Undergo MRI
Undergo nuclear study